The SARS-CoV-2 virus is notorious for eliciting a severe and complex inflammatory disease in its host, known as COVID-19. Many COVID-19 patients develop persistent olfactory dysfunction and debilitating cognitive impairments following infection, but the pathomechanistic cause of these neurological post-acute sequelae of COVID-19 (neuro-PASC) remains unknown. In the Lukens Lab, we are leveraging state-of-the-art transcriptomics technologies and transgenic reporter mice to understand how SARS-CoV-2 infection drives neuroinflammation and neurodegeneration in the olfactory neuroepithelium and brain. The overarching goal of our work is to develop novel therapies for the prevention and mitigation of neuro-PASC.